Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD

10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA

Several lipid-lowering treatments have been shown to exert CV benefits. Prof. Deepak Bhatt discusses how to integrate PCSK9 inhibitors into these therapies for primary and secondary CV prevention.

Video navigation menu

Impact of risk factors on CV events 01:16
Role of PCSK9 inhibition in primary & secondary prevention 03:15
New diabetes drugs with CV benefits 04:48
Bariatric surgery vs intensive medical therapy for diabetes 05:48
Effect of antithrombotic medication on CV events 07:38
How to integrate PCSK9 inhibition into current therapy? 12:28

Educational information

This video was recorded on October 26, 2017 in Boston and is a shortened version of the presentation prof. Bhatt gave there during the educational program 'Advances in Lipid Management and Cardiovascular Risk Reduction: New Horizons for 2018'

Faculty

Dr. Deepak L. Bhatt is the executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital (BWH). He is also a professor of medicine at Harvard Medical School (HMS) and editor-in-chief of the Harvard Heart Letter. Dr. Bhatt specializes in cardiovascular medicine and interventional cardiology.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme. PACE-cme did not receive financial support for the production of this recording.

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.